BioMérieux Outlines Ambitious Five-Year Strategic Growth Plan

bioMérieux, a global leader in in vitro diagnostics, announced its strategic growth initiative, GO•28, during a Capital Markets Day in Paris. The company's CEO, Pierre Boulud, along with the Executive Committee, shared the plan aimed at boosting sustainable growth and profitability.

GO•28 focuses on accelerating organic growth through continuous innovation and a comprehensive solutions portfolio. It also aims to streamline operations for better efficiency and engage more deeply in corporate social responsibility efforts. Emphasizing empowerment and agility within its workforce, bioMérieux strives to significantly contribute to global health.

The company targets a Compound Annual Growth Rate (CAGR) of +7% in organic revenue from 2024 to 2028. It also seeks to improve its Contributive Operating Income ratio to 20% by 2028, up from 16.5% in 2023, expecting at least a 10% annual increase in organic growth. Further, bioMérieux commits to a dividend policy ratio of about 25% and aims for a dramatic reduction in greenhouse gas emissions by 2030.